ArticleTurk patoloji dergisi2026
Role of PD-L1 in the Pathogenesis of Pre-Eclampsia and Its Association with Adverse Fetal Outcomes.
Article in Turk patoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gaps in maternal-fetal interface rejection response: chronic histiocytic intervillositis.Frontiers in immunology · 2025Review
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePreeclampsia is a pregnancy-specific disorder characterized by impaired maternal-fetal immune tolerance. The maternal immune system plays a crucial role in maintaining pregnancy, and its dysfunction is believed to contribute to preeclampsia. Immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), may play a key role in this process. This study evaluated PD-L1 expression in the placentae of patients with pre-eclampsia (PE) and eclampsia (EC). We also compared PD-L1 expression with histomorphological features and fetal outcomes. MATERIAL AND
methodsA prospective case-control study was conducted, including fifty pre-eclampsia cases, twenty-five eclampsia cases, and twenty-five normal pregnancy controls. Detailed clinicopathological data, histomorphological features of the placenta, and fetal outcomes were collected. PD-L1 expression was assessed using immunohistochemistry, with a semi-quantitative scoring system. The relationship between PD-L1 expression, histopathological scores, and fetal outcomes was also evaluated.
resultsIn this study, a lower expression of PD-L1 was observed in pre-eclampsia and eclampsia as compared to a normal pregnancy. Adverse fetal outcomes were associated with lower PD-L1 expression and with reduced placental weight and high histopathological scores ( > 5).
conclusionLower PD-L1 expression was observed in pre-eclampsia and eclampsia compared to normal pregnancies. Reduced PD-L1 expression correlated with histomorphological changes in the placenta and adverse fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.